Ja. Handler et al., Selective inhibition of phospholipases by atiprimod, a macrophage targeting antiarthritic compound, TOX APPL PH, 159(1), 1999, pp. 9-17
Azaspiranes are cationic amphiphilic compounds that are active in a number
of models of autoimmune disease and transplantation. Repeated administratio
n of cationic amphiphiles induces phospholipid accumulation in a variety of
species. The present study was conducted to explore the mechanism of phosp
holipid accumulation in rats caused by treatment with the novel azaspirane,
SK&F 106615 (atiprimod). Atiprimod inhibited the activities of partially p
urified phospholipases A(2) and C, but not D, in a noncompetitive manner in
vitro. Treatment of rats for 28 days with 10 mg/kg/day of atiprimod increa
sed the contents of arachidonate-containing molecular species within plasma
logen subclasses of hepatic phosphatidylcholine and phosphatidylethanolamin
e. In contrast, diacyl-linked species were not affected, indicating a selec
tive effect upon an hepatic plasmalogen-selective phospholipase A(2). Taken
together, the data suggest that the beneficial effects of atiprimod in aut
oimmune diseases may involve inhibition of phospholipase A(2) and C activit
ies. Further, the data suggest that atiprimod is a selective inhibitor of p
lasmalogen-selective phospholipase A(2) in vivo. (C) 1999 Academic Press.